Make the most of 2020. Read the FT in print for just $99.
Add this topic to your myFT Digest for news straight to your inbox
Prospect feared of resistance spreading to India and Africa
Scientists seek miracle drug to break parasites’ life cycle
Pharma companies must share intellectual property to spur the development of new treatments
Investing in intellectual property commercialisation is not without risks
Canadian drugmaker has been selling assets but retains net debt of more than $30bn
Drugmakers spot rewards despite the organisational difficulties
With millions of lives potentially at stake, UN agency issues call for new antibiotics
Shares rise on successful outcome for Lynparza, a drug tipped for blockbuster status
Drugmaker to focus on cutting $22bn debt pile as it targets double-digit growth
Spending on R&D has lagged behind the rest of the OECD countries
Declines in Crestor and Nexium offset emerging markets growth
Danish group is exposed to potential drug price curbs from Trump administration
Investor in early-stage drugmakers sets offer price of 207p a share
Comments come as Swiss drugmaker reports 4% increase in group sales
Move gives company more options but could signal less confidence in initial approach
French drugmaker faces questions over how to offset declining Lantus revenues
Several UK small-cap stocks stand out among their peers as ones to watch
Cheap credit and need for new drugs create overheated market, analysts warn
Swiss pharma group says treatment showed signs of outperforming others
Drug groups renew negotiations one week after discussions broke down
CMA alleges generic drugmaker overcharged NHS for hydrocortisone tablets
